Outcomes after ultramassive transfusion in the modern era: An Eastern Association for the Surgery of Trauma multicenter study.
Adult
Age Factors
Blood Component Transfusion
/ methods
Female
Glasgow Coma Scale
Hemorrhage
/ diagnosis
Hospital Mortality
Humans
Injury Severity Score
Male
Middle Aged
Prognosis
Resuscitation
/ methods
Retrospective Studies
Risk Factors
Thrombocytopenia
/ epidemiology
Trauma Centers
/ statistics & numerical data
Treatment Outcome
Wounds and Injuries
/ complications
Journal
The journal of trauma and acute care surgery
ISSN: 2163-0763
Titre abrégé: J Trauma Acute Care Surg
Pays: United States
ID NLM: 101570622
Informations de publication
Date de publication:
01 07 2021
01 07 2021
Historique:
entrez:
18
6
2021
pubmed:
19
6
2021
medline:
24
9
2021
Statut:
ppublish
Résumé
Despite the widespread institution of modern massive transfusion protocols with balanced blood product ratios, survival for patients with traumatic hemorrhage receiving ultramassive transfusion (UMT) (defined as ≥20 U of packed red blood cells [RBCs]) in 24 hours) remains low and resource consumption remains high. Therefore, we aimed to identify factors associated with mortality in trauma patients receiving UMT in the modern resuscitation era. An Eastern Association for the Surgery of Trauma multicenter retrospective study of 461 trauma patients from 17 trauma centers who received ≥20 U of RBCs in 24 hours was performed (2014-2019). Multivariable logistic regression and Classification and Regression Tree analysis were used to identify clinical characteristics associated with mortality. The 461 patients were young (median age, 35 years), male (82%), severely injured (median Injury Severity Score, 33), in shock (median shock index, 1.2; base excess, -9), and transfused a median of 29 U of RBCs, 22 U of fresh frozen plasma (FFP), and 24 U of platelets (PLT). Mortality was 46% at 24 hours and 65% at discharge. Transfusion of RBC/FFP ≥1.5:1 or RBC/PLT ≥1.5:1 was significantly associated with mortality, most pronounced for the 18% of patients who received both RBC/PLT and RBC/FFP ≥1.5:1 (odds ratios, 3.11 and 2.81 for mortality at 24 hours and discharge; both p < 0.01). Classification and Regression Tree identified that age older than 50 years, low initial Glasgow Coma Scale, thrombocytopenia, and resuscitative thoracotomy were associated with low likelihood of survival (14-26%), while absence of these factors was associated with the highest survival (71%). Despite modern massive transfusion protocols, one half of trauma patients receiving UMT are transfused with either RBC/FFP or RBC/PLT in unbalanced ratios ≥1.5:1, with increased associated mortality. Maintaining focus on balanced ratios during UMT is critical, and consideration of advanced age, poor initial mental status, thrombocytopenia, and resuscitative thoracotomy can aid in prognostication. Prognostic, level III.
Sections du résumé
BACKGROUND
Despite the widespread institution of modern massive transfusion protocols with balanced blood product ratios, survival for patients with traumatic hemorrhage receiving ultramassive transfusion (UMT) (defined as ≥20 U of packed red blood cells [RBCs]) in 24 hours) remains low and resource consumption remains high. Therefore, we aimed to identify factors associated with mortality in trauma patients receiving UMT in the modern resuscitation era.
METHODS
An Eastern Association for the Surgery of Trauma multicenter retrospective study of 461 trauma patients from 17 trauma centers who received ≥20 U of RBCs in 24 hours was performed (2014-2019). Multivariable logistic regression and Classification and Regression Tree analysis were used to identify clinical characteristics associated with mortality.
RESULTS
The 461 patients were young (median age, 35 years), male (82%), severely injured (median Injury Severity Score, 33), in shock (median shock index, 1.2; base excess, -9), and transfused a median of 29 U of RBCs, 22 U of fresh frozen plasma (FFP), and 24 U of platelets (PLT). Mortality was 46% at 24 hours and 65% at discharge. Transfusion of RBC/FFP ≥1.5:1 or RBC/PLT ≥1.5:1 was significantly associated with mortality, most pronounced for the 18% of patients who received both RBC/PLT and RBC/FFP ≥1.5:1 (odds ratios, 3.11 and 2.81 for mortality at 24 hours and discharge; both p < 0.01). Classification and Regression Tree identified that age older than 50 years, low initial Glasgow Coma Scale, thrombocytopenia, and resuscitative thoracotomy were associated with low likelihood of survival (14-26%), while absence of these factors was associated with the highest survival (71%).
CONCLUSION
Despite modern massive transfusion protocols, one half of trauma patients receiving UMT are transfused with either RBC/FFP or RBC/PLT in unbalanced ratios ≥1.5:1, with increased associated mortality. Maintaining focus on balanced ratios during UMT is critical, and consideration of advanced age, poor initial mental status, thrombocytopenia, and resuscitative thoracotomy can aid in prognostication.
LEVEL OF EVIDENCE
Prognostic, level III.
Identifiants
pubmed: 34144557
doi: 10.1097/TA.0000000000003121
pii: 01586154-202107000-00006
pmc: PMC8243874
mid: NIHMS1673275
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
24-33Subventions
Organisme : NIGMS NIH HHS
ID : K23 GM130892
Pays : United States
Organisme : NHLBI NIH HHS
ID : L30 HL138770
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL149670
Pays : United States
Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Callcut RAM, Kornblith LZM, Conroy ASB, et al. The why and how our trauma patients die: a prospective Multicenter Western Trauma Association study. J Trauma Acute Care Surg . 2019;86(5):864–870.
Dente CJ, Shaz BH, Nicholas JM, et al. Improvements in early mortality and coagulopathy are sustained better in patients with blunt trauma after institution of a massive transfusion protocol in a civilian level I trauma center. J Trauma . 2009;66(6):1616–1624.
Callcut RA, Johannigman JA, Kadon KS, Hanseman DJ, Robinson BR. All massive transfusion criteria are not created equal: defining the predictive value of individual transfusion triggers to better determine who benefits from blood. J Trauma . 2011;70(4):794–801.
Callcut RA, Cotton BA, Muskat P, et al. Defining when to initiate massive transfusion: a validation study of individual massive transfusion triggers in PROMMTT patients. J Trauma Acute Care Surg . 2013;74(1):59–65, 7-8; discussion 6-7.
Bawazeer M, Ahmed N, Izadi H, McFarlan A, Nathens A, Pavenski K. Compliance with a massive transfusion protocol (MTP) impacts patient outcome. Injury . 2015;46(1):21–28.
Holcomb JB, Tilley BC, Baraniuk S, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. JAMA . 2015;313(5):471–482.
Holcomb JB, del Junco DJ, Fox EE, et al. The prospective, observational, multicenter, major trauma transfusion (PROMMTT) study: comparative effectiveness of a time-varying treatment with competing risks. JAMA Surg . 2013;148(2):127–136.
Mesar T, Larentzakis A, Dzik W, Chang Y, Velmahos G, Yeh DD. Association between ratio of fresh frozen plasma to red blood cells during massive transfusion and survival among patients without traumatic injury. JAMA Surg . 2017;152(6):574–580.
Holcomb JB, Zarzabal LA, Michalek JE, et al. Increased platelet:RBC ratios are associated with improved survival after massive transfusion. J Trauma . 2011;71(2 Suppl 3):S318–S328.
Dzik WS, Ziman A, Cohn C, et al. Survival after ultramassive transfusion: a review of 1360 cases. Transfusion . 2016;56(3):558–563.
Velmahos GC, Chan L, Chan M, Tatevossian R, Cornwell EE 3rd, Asensio JA, Berne TV, Demetriades D. Is there a limit to massive blood transfusion after severe trauma? Arch Surg . 1998;133(9):947–952.
Yu AJ, Inaba K, Biswas S, de Leon LA, Wong M, Benjamin E, Lam L, Demetriades D. Supermassive transfusion: a 15-year single center experience and outcomes. Am Surg . 2018;84(10):1617–1621.
Ngo A, Masel D, Cahill C, Blumberg N, Refaai MA. Blood banking and transfusion medicine challenges during the COVID-19 pandemic. Clin Lab Med . 2020;40(4):587–601.
Feaster DJ, Mikulich-Gilbertson S, Brincks AM. Modeling site effects in the design and analysis of multi-site trials. Am J Drug Alcohol Abuse . 2011;37(5):383–391.
Therneau T, Atkinson B, Ripley B. Recursive Partitioning and Regression Trees 2019. Available at: https://CRAN.R-project.org/package=rpart . Accessed June 1, 2020.
Servia L, Montserrat N, Badia M, Llompart-Pou JA, Barea-Mendoza JA, Chico-Fernandez M, Sanchez-Casado M, Jimenez JM, Mayor DM, Trujillano J. Machine learning techniques for mortality prediction in critical traumatic patients: anatomic and physiologic variables from the RETRAUCI study. BMC Med Res Methodol . 2020;20(1):262.
Hsu CH, Haac BE, Drake M, et al. EAST Multicenter Trial on targeted temperature management for hanging-induced cardiac arrest. J Trauma Acute Care Surg . 2018;85(1):37–47.
Holcomb JB, Wade CE, Michalek JE, et al. Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. Ann Surg . 2008;248(3):447–458.
Allen CJ, Shariatmadar S, Meizoso JP, Hanna MM, Mora JL, Ray JJ, Namias N, Dudaryk R, Proctor KG. Liquid plasma use during “super” massive transfusion protocol. J Surg Res . 2015;199(2):622–628.
Sugiyama K, Fujita H, Nishimura S. Effects of in-house cryoprecipitate on transfusion usage and mortality in patients with multiple trauma with severe traumatic brain injury: a retrospective cohort study. Blood Transfus . 2020;18(1):6–12.
Inokuchi K, Sawano M, Yamamoto K, Yamaguchi A, Sugiyama S. Early administration of fibrinogen concentrates improves the short-term outcomes of severe pelvic fracture patients. Acute Med Surg . 2017;4(3):271–277.
Curry N, Foley C, Wong H, et al. Early fibrinogen concentrate therapy for major haemorrhage in trauma (E-FIT 1): results from a UK multi-centre, randomised, double blind, placebo-controlled pilot trial. Crit Care . 2018;22(1):164.
Shakur H, Roberts I, Bautista R, et al; CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet . 2010;376(9734):23–32.
Ramirez RJ, Spinella PC, Bochicchio GV. Tranexamic acid update in trauma. Crit Care Clin . 2017;33(1):85–99.
Stanworth SJ, New HV, Apelseth TO, et al. Effects of the COVID-19 pandemic on supply and use of blood for transfusion. Lancet Haematol . 2020;7(10):e756–e764.